The Hormone Receptor Positive HER2 Negative Clinical Stage II-III Breast Cancer (S2206)

Written By Erica Stupfel

In collaboration with MultiCare Institute for Research & Innovation, we have opened enrollment for the S2206 Hormone Receptor Positive HER2 Negative Clinical Stage II-III Breast Cancer trial.

The Hormone Receptor Positive HER2 Negative Clinical Stage II-III Breast Cancer (S2206) trial compares breast cancer event-free survival among participants receiving standard neoadjuvant chemotherapy alone versus neoadjuvant chemotherapy concurrent with durvalumab.

What makes this trial unique is the user-friendly design, which simplifies participation for institutions and reduces barriers to patient eligibility. Our hope is that these studies serve two-fold: yielding valuable insights into lung and breast cancer research today, and establishing a precedent for the design, accessibility, and the diversity of patient populations for future trials.

In partnership with MultiCare, Northwest Medical Specialties, the Southwest Oncology Group (SWOG), and other medical institutions at the forefront of cancer care and research, we are collectively working towards a future where groundbreaking treatments and research are accessible to all who need it.

Erica Stupfel

e*design Creative Services specializes in making professional design available to small companies and individuals. I understand the importance in brand identity and how a positive visual representation of your product or service can make the difference between success and failure. Your ideas and vision combined with my marketing and design expertise will be a sure success story.

https://www.edesigncreative.com
Previous

Glioma- Neonc Technologies- NEO100-01
Next

The Pragmatica-Lung Study (S2302)